MX2019000600A - Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello. - Google Patents

Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.

Info

Publication number
MX2019000600A
MX2019000600A MX2019000600A MX2019000600A MX2019000600A MX 2019000600 A MX2019000600 A MX 2019000600A MX 2019000600 A MX2019000600 A MX 2019000600A MX 2019000600 A MX2019000600 A MX 2019000600A MX 2019000600 A MX2019000600 A MX 2019000600A
Authority
MX
Mexico
Prior art keywords
skin
hydroxytryptamine
receptor
hair repair
stimulating agent
Prior art date
Application number
MX2019000600A
Other languages
English (en)
Inventor
Bruno Chretien Fabrice
Gaillard Raphael
Rocheteau Pierre
Torno Nicolas
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2019000600A publication Critical patent/MX2019000600A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4933—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having sulfur as an exocyclic substituent, e.g. pyridinethione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits
    • A61K2800/884—Sequential application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente invencion se refiere al campo de la reparacion de la piel y/o del cabello, con fines terapeuticos y cosmeticos; mas especificamente, se refiere a un agente que estimula el receptor de 5-hidroxitriptamina 1B, para usarse en el refuerzo de la reparacion de la piel y/o del cabello.
MX2019000600A 2016-07-15 2017-07-13 Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello. MX2019000600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2016001136 2016-07-15
PCT/EP2017/067791 WO2018011382A1 (en) 2016-07-15 2017-07-13 5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair

Publications (1)

Publication Number Publication Date
MX2019000600A true MX2019000600A (es) 2019-06-13

Family

ID=56787641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000600A MX2019000600A (es) 2016-07-15 2017-07-13 Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.

Country Status (10)

Country Link
US (1) US20190290641A1 (es)
EP (1) EP3484462B1 (es)
JP (1) JP2019524723A (es)
KR (1) KR20190038840A (es)
CN (1) CN110022869A (es)
AU (1) AU2017295038B2 (es)
BR (1) BR112019000706A8 (es)
CA (1) CA3030054A1 (es)
MX (1) MX2019000600A (es)
WO (1) WO2018011382A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348486A (zh) 2015-07-17 2018-07-31 巴斯德研究院 用作卫星细胞自我更新和/或分化的启动子的5-羟色胺1b受体激动剂
US11013830B2 (en) 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
MX2020014286A (es) * 2018-06-20 2021-03-25 Lts Lohmann Therapie Systeme Ag Sistema terapeutico transdermico que contiene asenapina.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63203625A (ja) 1987-02-19 1988-08-23 Kao Corp ５α−リダクタ−ゼ阻害剤
FR2739553B1 (fr) 1995-10-06 1998-01-02 Oreal Utilisation d'antagonistes de la bradykinine pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
FR2758263B1 (fr) * 1997-01-16 1999-12-17 Oreal Utilisation d'un antagoniste ou d'un agoniste de serotonine specifiques respectivement du recepteur 5ht2 et 5ht1d dans une composition cosmetique ou dermatologique pour peaux sensibles et composition obtenue
FR2778558B1 (fr) 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
ES2147538B1 (es) 1999-01-29 2001-04-01 Revlon Consumer Prod Corp Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
JP3441665B2 (ja) 1999-02-04 2003-09-02 株式会社資生堂 （２−置換オキシフェニル）アルカンアミド誘導体及び養毛剤、皮膚外用剤
US20060052405A1 (en) 2000-07-19 2006-03-09 Knowles W R Hair loss prevention
FR2812192B1 (fr) 2000-07-28 2003-01-31 Oreal Utilisation d'antagonistes de recepteur des prostaglandines ep-3 comme agent cosmetique permettant d'attenuer, de diminuer ou d'arreter la chute des cheveux et des poils
ATE316387T1 (de) * 2000-09-22 2006-02-15 Perlei Medical Produkte Gmbh Verwendung von antifibrinolytika für die präparation und herstellung von tupfern, kompressen oder pflaster
ATE337009T1 (de) 2001-05-31 2006-09-15 Pfizer Prod Inc Medizinische verwendung thyromimetischer verbindungen gegen haarausfall und zusammensetzungen
WO2003041669A1 (en) 2001-09-28 2003-05-22 Lg Household & Health Care Ltd. A composition for promoting hair growth
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US6860042B2 (en) 2002-07-19 2005-03-01 Walker-Dawson Interests, Inc. Excavation system employing a jet pump
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
AU2003274569B2 (en) 2002-11-12 2008-07-31 Warner-Lambert Company Llc Method of stimulating hair growth using benzopyrans
CA2511089A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc Androgen receptor antagonists
OA13170A (en) 2003-05-22 2006-12-13 Pharmacia Italia Spa Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
US20050118282A1 (en) 2003-09-16 2005-06-02 Aphios Corporation Compositions and methods for inhibiting 5-alpha reductase
AR041407A1 (es) 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
US20060009430A1 (en) 2004-07-01 2006-01-12 Kelly Gregory J Composition for the prevention and treatment of the detrimental effects of dihydrotestosterone
WO2006006065A1 (en) 2004-07-08 2006-01-19 Warner-Lambert Company Llc Androgen modulators
DE202006007482U1 (de) 2006-05-10 2006-07-20 Sentner, Thomas Leuchtmöbel
BRPI0713425A2 (pt) * 2006-06-16 2012-03-13 H. Lundbeck A/S composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
US9221779B2 (en) * 2006-06-22 2015-12-29 Ramot At Tel-Aviv University Ltd. Serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
FR2903984B1 (fr) 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
WO2008084286A2 (en) * 2006-10-25 2008-07-17 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
ITTO20060918A1 (it) * 2006-12-22 2008-06-23 Chiara Cesano Composizione cosmetica e farmaceutica e mezzo di coltura per la rigenerazione del tessuto cutaneo, e relativi usi
WO2008078353A1 (en) * 2006-12-22 2008-07-03 Medestea Internazionale S.P.A. A novel use of antidepressant compounds and related compositions
US8680134B2 (en) * 2009-10-23 2014-03-25 Avi Dascalu Triptans for the treatment of psoriasis
AU2011269989B2 (en) 2010-06-23 2014-12-11 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
AU2013305563B2 (en) * 2012-08-24 2018-09-27 Integurx Therapeutics, Llc Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents
US20160101093A1 (en) * 2013-05-21 2016-04-14 Jason B. Wynberg Methods for the treatment of premature ejaculation
US9399039B1 (en) * 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use

Also Published As

Publication number Publication date
JP2019524723A (ja) 2019-09-05
US20190290641A1 (en) 2019-09-26
WO2018011382A1 (en) 2018-01-18
CA3030054A1 (en) 2018-01-18
EP3484462B1 (en) 2022-12-14
BR112019000706A8 (pt) 2022-12-06
KR20190038840A (ko) 2019-04-09
AU2017295038A1 (en) 2019-01-24
EP3484462A1 (en) 2019-05-22
CN110022869A (zh) 2019-07-16
BR112019000706A2 (pt) 2019-05-07
AU2017295038B2 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
CY1122603T1 (el) Γαμμα-δικετονες για τη θεραπευτικη αντιμετωπιση και την προληψη της γηρανσης του δερματος και των ρυτιδων
EA202091134A1 (ru) Экзосомы для иммуноонкологической и противовоспалительной терапии
PH12018502429A1 (en) Antibody molecules for cancer treatment
CY1124595T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
TWD170518S (zh) 美容器具
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2015011296A (es) Dispositivo foto-terapeutico, metodo y uso.
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
EA201991997A1 (ru) Комбинированная терапия
CA189459S (en) Cosmetic skin treatment apparatus
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
NZ773981A (en) Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
IL257670A (en) Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
PH12020500029A1 (en) Cosmetic compositions and methods of use
GB2582683B (en) Composition for the care of human hair
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
MX2019000600A (es) Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины